JENKINTOWN, PA — SFA Therapeutics, Inc. has announced encouraging results from its Phase 1b clinical trial of SFA-002, an oral drug candidate aimed at treating mild-to-moderate psoriasis. The study demonstrated both safety and efficacy, bolstering hopes for a patient-friendly alternative in managing this chronic skin condition.
The trial reached its primary endpoint of safety, with no treatment-related adverse events or toxicities observed, and no rebound effects encountered during the treatment period. Additionally, the drug produced statistically significant improvements in Psoriasis Area and Severity Index (PASI) and Investigator Global Assessment (IGA) scores compared to placebo, addressing key measurements of disease severity and progression.
“This study underscores the potential of SFA-002 to provide relief for patients with mild-to-moderate psoriasis in a safe and effective manner,” said Dr. Stefan Weiss, Chief Medical Officer of SFA Therapeutics. The study, which was conducted in two formulations, showed particularly promising results in its Cohort 2 group, paving the way for its advancement to a Phase 2 clinical trial.
The potential significance of SFA-002 lies in its targeted and non-immunosuppressive approach to immune regulation, a departure from traditional treatments that often suppress the entire immune system. According to company data, mild-to-moderate psoriasis accounts for over 80% of all plaque psoriasis cases, yet effective oral treatment options for this population remain scarce.
“SFA-002 addresses a critical gap in care for these patients by combining an oral administration route with a highly focused mechanism of action,” said Ira Spector, PhD, CEO of SFA Therapeutics. The company plans to continue exploring the Cohort 2 formulation in the upcoming Phase 2 trial, with the goal of demonstrating its long-term benefits and improved treatment outcomes for psoriasis patients.
If SFA-002 successfully advances through further phases of development, it could represent a breakthrough in managing plaque psoriasis, offering patients a safer and more convenient option in their treatment regimen. With a strong foundation of safety and efficacy, SFA Therapeutics is well-positioned to reshape the landscape for psoriasis care.
For the latest news on everything happening in Chester County and the surrounding area, be sure to follow MyChesCo on Google News and MSN.